<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03315000</url>
  </required_header>
  <id_info>
    <org_study_id>VIL-2017</org_study_id>
    <nct_id>NCT03315000</nct_id>
  </id_info>
  <brief_title>Effect of Vilanterol on Methacholine Challenge Results</brief_title>
  <official_title>The Effect of Vilanterol Against Methacholine-induced Bronchoconstriction in Mild Asthmatics</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Saskatchewan</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Saskatchewan</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study will assess the degree of bronchoprotection provided by the ultra long-acting beta2
      agonist vilanterol against methacholine-induced bronchoconstriction.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This will be a double-blind, three-way crossover study comparing combination
      vilanterol+fluticasone with fluticasone monotherapy and a placebo (vilanterol is not
      available as a monotherapy). The order in which the treatments are given will be randomized
      and each treatment will be separated by a minimum one-week washout. Fifteen asthmatic
      participants will be recruited from the local community. Methacholine challenge testing (MCT)
      with the two-minute tidal breathing protocol will be used to quantify the bronchoprotective
      effects (if any) of each treatment against methacholine-induced bronchoconstriction.

      Each participant will undergo a total of nine methacholine challenges. After a baseline
      methacholine challenge, the randomized treatment (identity unknown to investigator or
      participant) will be administered through an Ellipta速 (multi-dose dry powder inhaler). Thirty
      minutes following treatment administration, a second methacholine challenge will be
      performed. At 24 hours post-treatment, each participant must re-visit the lab for one
      methacholine challenge. The same process will be followed for each treatment.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 13, 2017</start_date>
  <completion_date type="Anticipated">May 1, 2018</completion_date>
  <primary_completion_date type="Anticipated">May 1, 2018</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline methacholine PC20 (bronchoprotection) at 30 min post-treatment</measure>
    <time_frame>baseline versus 30 min post-treatment</time_frame>
    <description>assessed by dose shift of geometric mean methacholine PC20 data</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline methacholine PC20 (bronchoprotection) at 24 hours post-treatment</measure>
    <time_frame>baseline versus 24 hours post-treatment</time_frame>
    <description>assessed by dose shift of geometric mean methacholine PC20 data</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">15</enrollment>
  <condition>Asthma</condition>
  <arm_group>
    <arm_group_label>Vilanterol</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Vilanterol (25mcg)+ fluticasone (100mcg) inhaled through Ellipta速 inhaler</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Fluticasone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Fluticasone (100mcg) monotherapy inhaled through Ellipta速 inhaler</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Lactose powder inhaled through Ellipta速 inhaler</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vilanterol and Fluticasone Furoate</intervention_name>
    <description>Same as vilanterol arm description</description>
    <arm_group_label>Vilanterol</arm_group_label>
    <other_name>Breo</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fluticasone Furoate</intervention_name>
    <description>Same as fluticasone arm description</description>
    <arm_group_label>Fluticasone</arm_group_label>
    <other_name>Arnuity</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebos</intervention_name>
    <description>Same as placebo arm description</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>lactose powder</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  men and women aged 18 or older

          -  stable mild-to-moderate asthma

          -  baseline methacholine PC20 less than or equal to 8mg/mL

          -  FEV1 greater than or equal to 65% of predicted

        Exclusion Criteria:

          -  Use of long-acting anticholinergic or long-acting beta2 agonist within 30 days of
             study

          -  pregnant or nursing

          -  diabetes

          -  hypokalemia

          -  cardiovascular, prostate, kidney, or urinary retention problems

          -  lactose-intolerant

          -  allergy-induced asthma symptoms or upper respiratory tract infection within four weeks
             of study

          -  current smokers

          -  past smokers with smoking history &gt;10 pack years
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Don Cockcroft, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Saskatchewan</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Don Cockcroft, MD</last_name>
    <phone>306-844-1446</phone>
    <email>don.cockcroft@usask.ca</email>
  </overall_contact>
  <location>
    <facility>
      <name>Asthma Research Lab - University of Saskatchewan</name>
      <address>
        <city>Saskatoon</city>
        <state>Saskatchewan</state>
        <zip>S7N 0W8</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Don Cockcroft, MD</last_name>
      <phone>306-844-1446</phone>
      <email>don.cockcroft@usask.ca</email>
    </contact>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>October 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 16, 2017</study_first_submitted>
  <study_first_submitted_qc>October 16, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">October 19, 2017</study_first_posted>
  <last_update_submitted>October 16, 2017</last_update_submitted>
  <last_update_submitted_qc>October 16, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 19, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Saskatchewan</investigator_affiliation>
    <investigator_full_name>Don Cockcroft</investigator_full_name>
    <investigator_title>Professor, Department of Medicine</investigator_title>
  </responsible_party>
  <keyword>methacholine</keyword>
  <keyword>airway hyperresponsiveness</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fluticasone</mesh_term>
    <mesh_term>Methacholine Chloride</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Journal Publication</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

